Literature DB >> 19201716

Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension.

Matthew J Hegewald1, C Gregory Elliott2.   

Abstract

Pulmonary hypertension is an important complication of COPD. A small subset of patients with COPD have severe pulmonary hypertension (PH) that is out of proportion to the mild increase in pulmonary arterial pressure observed commonly. Severe PH associated with COPD is associated with increased morbidity and mortality. Treatment options in this group of patients are limited with no conclusive evidence of benefit when drugs approved for treatment of pulmonary arterial hypertension are used. We describe a patient with severe PH associated with COPD who improved clinically and hemodynamically when treated with inhaled iloprost. The improvement was sustained for 2 years. Severe PH in patients with COPD needs to be recognized and novel treatment approaches considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201716     DOI: 10.1378/chest.08-1515

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension.

Authors:  Gulsev Ozen; Chabha Benyahia; Salma Mani; Kamel Boukais; Adam M Silverstein; Richard Bayles; Andrew C Nelsen; Yves Castier; Claire Danel; Hervé Mal; Lucie H Clapp; Dan Longrois; Xavier Norel
Journal:  Br J Pharmacol       Date:  2019-10-31       Impact factor: 8.739

Review 2.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 3.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

4.  Efficacy of inhaled iloprost in cor pulmonale and severe pulmonary hypertension associated with tuberculous destroyed lung.

Authors:  Yae Min Park; Wook-Jin Chung; Sang Pyo Lee; Deok Young Choi; Han Joo Baek; Sung Hwan Jung; In Suck Choi; Eak Kyun Shin
Journal:  J Cardiovasc Ultrasound       Date:  2014-06-30

5.  The use of iloprost in the treatment of 'out of proportion' pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Bartosz Lasota; Szymon Skoczyński; Katarzyna Mizia-Stec; Władysław Pierzchała
Journal:  Int J Clin Pharm       Date:  2013-04-03

6.  Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts.

Authors:  Anna-Karin Larsson-Callerfelt; Oskar Hallgren; Annika Andersson-Sjöland; Lena Thiman; Johan Björklund; Josefine Kron; Kristian Nihlberg; Leif Bjermer; Claes-Göran Löfdahl; Gunilla Westergren-Thorsson
Journal:  Respir Res       Date:  2013-02-14

7.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 8.  Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD.

Authors:  J Michael Wells; Mark T Dransfield
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-10-29

9.  Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.

Authors:  Sina Saffaran; Wenfei Wang; Anup Das; Walter Schmitt; Eva-Maria Becker-Pelster; Jonathan G Hardman; Gerrit Weimann; Declan G Bates
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-07-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.